Corcept Therapeutics Inc

Corcept Therapeutics Inc


Market Cap$3.47B

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Corcept Therapeutics IncCorcept Therapeutics Inc29.40%-6.9-

Target Price by Analysts

29.1% upsideCorcept Therapeutics Target Price DetailsTarget Price

Current Fair Value

137.4% upside

Undervalued by 137.4% based on the discounted cash flow analysis.

Share Statistics

Market cap$3.47 Billion
Enterprise Value-
Dividend Yield$0.0 (0.0%)
Earnings per Share$1.07
Outstanding Shares104,110,000
Avg 30 Day Volume893,897


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio29.37
Price to Sales6.9
Price to Book Ratio-
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income0
Total Debt to Enterprise-
Debt to Equity-

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Corcept Therapeutics Inc

CEO: Joseph Belanoff

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...